Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage
Publishing timestamp: 2023-02-17 10:29:11
Summary
Japanese drugmaker Eisai expects the FDA to fully approve its Alzheimer's treatment Leqembi this summer, which would expand access to the pricey new antibody under Medicare. Eisai has completed its phase three trial and is no longer enrolling patients, so the medication is currently out of reach for most, except very wealthy. If everything goes according to Eisai's expectations, FDA would grant full approval and CMS would provide unrestricted coverage of Leqembi. Eisai anticipates that about 100000 diagnosed early Alzheimer's patients will be eligible by year three of drug's rollout. Medicare's coverage policy is controversial, and the Alzheimer's Association has called for full and unrestricted coverage of Leqembi.
Sentiment: POSITIVE
Tickers: BIIB, 4523.T-JP, ESALY,
Keywords: coronavirus, eisai co ltd, politics, business, u.s. economy, health care industry, biogen inc, pandemics, biotechnology, disease outbreaks, business news, breaking news: business, biotech and pharmaceuticals, epidemics,